All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On January 27, 2023, it was announced that the U.S. Food and Drug Administration (FDA) had granted approval to pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL) after ≥2 prior lines of systemic therapy, including a previous BTK inhibitor.1
Pirtobrutinib was granted approval under the FDA's Accelerated Approval pathway based on key data from the phase I/II BRUIN trial (NCT03740529). Data was obtained from a subset of 120 patients with MCL, treated with pirtobrutinib 200 mg once daily until disease progression or unacceptable toxicity. The key efficacy outcomes were:
Serious adverse reactions occurred in 38% of patients. The most commonly reported serious adverse reactions were:
The approval of pirtobrutinib provides a new treatment option for patients with relapsed/refractory MCL, including those who have received prior covalent BTK inhibitors.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox